CY1124407T1 - Ενωσεις αναστολεα αυτοταξινης - Google Patents
Ενωσεις αναστολεα αυτοταξινηςInfo
- Publication number
- CY1124407T1 CY1124407T1 CY20211100562T CY211100562T CY1124407T1 CY 1124407 T1 CY1124407 T1 CY 1124407T1 CY 20211100562 T CY20211100562 T CY 20211100562T CY 211100562 T CY211100562 T CY 211100562T CY 1124407 T1 CY1124407 T1 CY 1124407T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compounds
- inhibitor compounds
- autotaxin inhibitor
- autotaxin
- methods
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 229940122849 Autotaxin inhibitor Drugs 0.000 title 1
- 102100021977 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Human genes 0.000 abstract 2
- 108050004000 Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361907965P | 2013-11-22 | 2013-11-22 | |
| US201462038121P | 2014-08-15 | 2014-08-15 | |
| PCT/US2014/066706 WO2015077503A1 (en) | 2013-11-22 | 2014-11-20 | Autotaxin inhibitor compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124407T1 true CY1124407T1 (el) | 2022-07-22 |
Family
ID=53180152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100562T CY1124407T1 (el) | 2013-11-22 | 2021-06-23 | Ενωσεις αναστολεα αυτοταξινης |
Country Status (31)
| Country | Link |
|---|---|
| US (7) | US9334261B2 (enExample) |
| EP (2) | EP3878848A1 (enExample) |
| JP (1) | JP6501367B2 (enExample) |
| KR (2) | KR102515248B1 (enExample) |
| CN (2) | CN105793253B (enExample) |
| AU (2) | AU2014352888B2 (enExample) |
| BR (1) | BR112016010220B1 (enExample) |
| CA (1) | CA2930737C (enExample) |
| CL (1) | CL2016001231A1 (enExample) |
| CR (2) | CR20190394A (enExample) |
| CY (1) | CY1124407T1 (enExample) |
| DK (1) | DK3071561T3 (enExample) |
| EA (1) | EA030068B1 (enExample) |
| ES (1) | ES2875899T3 (enExample) |
| HR (1) | HRP20210957T1 (enExample) |
| HU (1) | HUE055213T2 (enExample) |
| IL (2) | IL245383B (enExample) |
| LT (1) | LT3071561T (enExample) |
| MX (2) | MX375706B (enExample) |
| MY (1) | MY182095A (enExample) |
| NI (1) | NI201600071A (enExample) |
| NZ (1) | NZ720478A (enExample) |
| PE (1) | PE20160654A1 (enExample) |
| PH (1) | PH12016500862B1 (enExample) |
| PL (1) | PL3071561T3 (enExample) |
| PT (1) | PT3071561T (enExample) |
| RS (1) | RS62027B1 (enExample) |
| SI (1) | SI3071561T1 (enExample) |
| SM (1) | SMT202100531T1 (enExample) |
| WO (1) | WO2015077503A1 (enExample) |
| ZA (2) | ZA201603083B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2861566T1 (sl) | 2012-06-13 | 2017-03-31 | F. Hoffmann-La Roche Ag | Novi diazaspirocikloalkan in azaspirocikloalkan |
| PL2900669T3 (pl) | 2012-09-25 | 2020-01-31 | F. Hoffmann-La Roche Ag | Pochodne heksahydropirolo[3,4-C]pirolu i związki pokrewne jako inhibitory autotaksyny (ATX) oraz inhibitory produkcji kwasu lizofosfatydowego (LPA) do leczenia np. chorób nerek |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| EP3046909A4 (en) | 2013-09-17 | 2017-03-29 | Pharmakea, Inc. | Heterocyclic vinyl autotaxin inhibitor compounds |
| US9714240B2 (en) | 2013-09-17 | 2017-07-25 | Pharmakea, Inc. | Vinyl autotaxin inhibitor compounds |
| US9850203B2 (en) | 2013-09-26 | 2017-12-26 | Pharmakea, Inc. | Autotaxin inhibitor compounds |
| CA2930735A1 (en) | 2013-11-22 | 2015-05-28 | Sabre Therapeutics Llc | Tetracyclic autotaxin inhibitors |
| PE20160654A1 (es) | 2013-11-22 | 2016-07-15 | Pharmakea Inc | Compuestos de inhibidor de autotaxina |
| AU2014356583B2 (en) | 2013-11-26 | 2019-02-28 | F. Hoffmann-La Roche Ag | New octahydro-cyclobuta (1,2-c;3,4-c')dipyrrol-2-yl |
| CR20160418A (es) | 2014-03-26 | 2016-11-07 | Hoffmann La Roche | Nuevos compuestos biciclicos de 7 eslabones |
| MA50635A (fr) | 2014-03-26 | 2020-08-12 | Hoffmann La Roche | Nouveaux composés bicycliques comme inhibiteurs de la production d'autotaxin (atx) et de l'acide lysophosphatidique |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| CN116059203A (zh) | 2015-05-27 | 2023-05-05 | 赛博治疗有限责任公司 | 自分泌运动因子抑制剂及其用途 |
| EP3344619B1 (en) | 2015-09-04 | 2020-10-28 | H. Hoffnabb-La Roche Ag | Phenoxymethyl derivatives |
| WO2017050747A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual atx/ca inhibitors |
| BR112018006080A2 (pt) | 2015-09-24 | 2018-10-09 | F. Hoffmann-La Roche Ag | novos compostos bicíclicos como inibidores de dupla ação de atx/ca |
| MA42918A (fr) | 2015-09-24 | 2018-08-01 | Hoffmann La Roche | Composés bicycliques utilisés en tant qu'inhibiteurs d'atx |
| AU2016328437A1 (en) | 2015-09-24 | 2018-01-25 | F. Hoffmann-La Roche Ag | Bicyclic compounds as ATX inhibitors |
| US11000142B2 (en) | 2016-12-06 | 2021-05-11 | John Joseph Girard | Flexible floor mat incorporating LED lighting |
| RU2019132254A (ru) | 2017-03-16 | 2021-04-16 | Ф. Хоффманн-Ля Рош Аг | Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca |
| EP3596060B1 (en) | 2017-03-16 | 2023-09-20 | F. Hoffmann-La Roche AG | New bicyclic compounds as atx inhibitors |
| MX2020002241A (es) | 2017-08-28 | 2020-09-03 | Angiex Inc | Anticuerpos anti-tm4sf y métodos de uso de los mismos. |
| MX2021010254A (es) | 2019-02-27 | 2021-09-21 | Angiex Inc | Conjugados de anticuerpo-farmaco que comprenden anticuerpos anti-tm4sf1 y metodos de uso de los mismos. |
| AU2023265017A1 (en) * | 2022-05-03 | 2024-12-12 | Df 2024 Ip Acquisition, Llc | Polymorphic and salt forms of the autotaxin inhibitor cudetaxestat |
| CN116239577A (zh) * | 2023-03-27 | 2023-06-09 | 沈阳药科大学 | 一种制备Cudetaxestat的方法 |
| CN116396205B (zh) * | 2023-04-20 | 2024-10-01 | 沈阳药科大学 | 一种n-芳基吲哚衍生物及其制备方法和应用 |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5210574A (en) | 1991-03-08 | 1993-05-11 | Mita Industrial Co., Ltd. | Photosensitive drum body-mounting mechanism including a drive coupling member with a coupling protrusion adapted to bite into the inner surface of the mechanism's photosensitive drum |
| US5186522A (en) | 1991-09-24 | 1993-02-16 | Midland Brake, Inc. | Air dryer purge line |
| DE69316741T2 (de) | 1992-11-10 | 1998-09-10 | Caterpillar Inc | Magnetventil |
| US5407368A (en) | 1992-12-15 | 1995-04-18 | Minnesota Mining And Manufacturing Company | Electrode connector |
| US5761473A (en) | 1993-01-08 | 1998-06-02 | International Business Machines Corporation | Method and system for increased instruction synchronization efficiency in a superscalar processsor system utilizing partial data dependency interlocking |
| US5564949A (en) | 1995-01-05 | 1996-10-15 | Thomas & Betts Corporation | Shielded compact data connector |
| JP2664048B2 (ja) | 1995-03-27 | 1997-10-15 | 科学技術庁金属材料技術研究所長 | 六フッ化二ケイ素の合成法 |
| GB9514473D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
| CA2386750A1 (en) | 1999-10-22 | 2001-05-03 | Merck & Co. Inc. | Pharmaceuticals for treating obesity |
| US6890933B1 (en) | 2000-02-24 | 2005-05-10 | President And Fellows Of Harvard College | Kinesin inhibitors |
| AU2002213421A1 (en) | 2000-10-03 | 2002-04-15 | Lilly Icos Llc | Condensed pyridoindole derivatives |
| BR0208790A (pt) | 2001-04-11 | 2004-03-30 | Idenix Cayman Ltd | Fenilindoìs para o tratamento de hiv |
| DE60203529T2 (de) | 2001-09-27 | 2006-03-16 | F. Hoffmann-La Roche Ag | Indolderivate als cox-ii-inhibitoren |
| US7528165B2 (en) | 2001-12-13 | 2009-05-05 | National Health Research Institutes | Indole compounds |
| WO2004019869A2 (en) | 2002-08-29 | 2004-03-11 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
| CA2495943C (en) | 2002-08-29 | 2009-07-21 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
| AU2004240649A1 (en) | 2003-05-19 | 2004-12-02 | Irm, Llc | Immunosuppressant compounds and compositions |
| EP1701940B1 (en) | 2003-12-23 | 2008-05-28 | H.Lundbeck A/S | 2-(1h-indolylsulfanyl)-benzyl amine derivatives as ssri |
| WO2005111278A1 (ja) | 2004-05-19 | 2005-11-24 | Sumitomo Electric Industries, Ltd. | Ｉｉｉ族窒化物半導体結晶およびその製造方法ならびにｉｉｉ族窒化物半導体デバイス |
| KR101141650B1 (ko) | 2004-09-30 | 2012-05-17 | 엘지전자 주식회사 | 매체접속제어 계층에서의 데이터 처리 방법 및 이동통신용단말 |
| WO2006041961A1 (en) | 2004-10-05 | 2006-04-20 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTHAND HUMAN SERVICES | Arylthioindole tubulin polymerization inhibitors and methods of treating or preventing cancer using same |
| US20080319044A1 (en) | 2004-11-01 | 2008-12-25 | Nuada, Llc | Compounds and Methods of Use Thereof |
| WO2007134169A2 (en) | 2006-05-10 | 2007-11-22 | Nuada, Llc | Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof |
| US20060270634A1 (en) | 2005-05-06 | 2006-11-30 | Miller Duane D | Acetal phosphate-derived LPA mimics, PPARgamma activators, and autotaxin inhibitors |
| AR054394A1 (es) | 2005-06-17 | 2007-06-20 | Lundbeck & Co As H | Derivados de 2- (1h-indolilsulfanil)-aril amina |
| WO2007041600A2 (en) | 2005-10-03 | 2007-04-12 | Luminescent Technologies, Inc. | Mask-pattern determination using topology types |
| ATE526318T1 (de) | 2005-12-19 | 2011-10-15 | Glaxosmithkline Llc | Farnesoid-x-rezeptor-agonisten |
| WO2008157361A1 (en) | 2007-06-15 | 2008-12-24 | University Of Utah Research Foundation | α-CHLORO AND α-BROMO PHOSPHONATE ANALOGS OF LYSOPHOSPHATIDIC ACID AND METHODS OF MAKING AND USING THEREOF |
| DE102007047735A1 (de) | 2007-10-05 | 2009-04-09 | Merck Patent Gmbh | Thiazolderivate |
| DE102007047738A1 (de) | 2007-10-05 | 2009-04-09 | Merck Patent Gmbh | Imidazolderivate |
| DE102007047737A1 (de) | 2007-10-05 | 2009-04-30 | Merck Patent Gmbh | Piperidin- und Piperazinderivate |
| US8268891B1 (en) | 2007-11-13 | 2012-09-18 | University Of Memphis Research Foundation | Autotaxin inhibitors |
| US8378100B2 (en) | 2008-01-09 | 2013-02-19 | University Of Virginia Patent Foundation | Phosphonate derivatives as autotaxin inhibitors |
| US20110110886A1 (en) | 2008-06-13 | 2011-05-12 | Yale University | Small molecule inhibitors of autotaxin and methods of use |
| WO2010040080A1 (en) | 2008-10-03 | 2010-04-08 | Abby Louise Parrill-Baker | Mechanism-based inactivators of autotaxin |
| DE102008059578A1 (de) | 2008-11-28 | 2010-06-10 | Merck Patent Gmbh | Benzo-Naphtyridin Verbindungen |
| US8530650B2 (en) | 2008-12-01 | 2013-09-10 | Merck Patent Gmbh | 2, 5-diamino-substituted pyrido [4, 3-D] pyrimidines as autotaxin inhibitors against cancer |
| JP5767205B2 (ja) * | 2009-04-02 | 2015-08-19 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | オートタキシン阻害剤としての複素環式化合物 |
| US8329907B2 (en) | 2009-04-02 | 2012-12-11 | Merck Patent Gmbh | Autotaxin inhibitors |
| AU2010234087B2 (en) | 2009-04-02 | 2016-05-12 | Merck Patent Gmbh | Piperidine and piperazine derivatives as autotaxin inhibitors |
| US8445200B2 (en) | 2009-04-15 | 2013-05-21 | The Regents Of The University Of California | Genotoxicity as a biomarker for inflammation |
| CN102481269B (zh) | 2009-05-11 | 2015-10-07 | 博格有限责任公司 | 包含辅酶q10的药物组合物及其制备方法 |
| CA2763016C (en) | 2009-05-20 | 2018-04-17 | Eth Zurich | Targeting micrornas for metabolic disorders |
| WO2011002918A1 (en) | 2009-06-30 | 2011-01-06 | The University Of Memphis Research Foundation | Novel diverse lead compound autotaxin inhibitors |
| DE102009033392A1 (de) | 2009-07-16 | 2011-01-20 | Merck Patent Gmbh | Heterocyclische Verbindungen als Autotaxin-Inhibitoren II |
| DE102009049211A1 (de) | 2009-10-13 | 2011-04-28 | Merck Patent Gmbh | Sulfoxide |
| WO2011049433A1 (en) | 2009-10-23 | 2011-04-28 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Diagnosis and treatment of pruritis |
| WO2011053597A1 (en) | 2009-10-26 | 2011-05-05 | The University Of Memphis Research Foundation | Pipemidic acid derivative autotaxin inhibitors |
| US8497371B2 (en) | 2009-10-26 | 2013-07-30 | University Of Memphis Research Foundation | Pipemidic acid derivative autotaxin inhibitors |
| US9187471B2 (en) | 2010-02-19 | 2015-11-17 | Medivation Technologies, Inc. | Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use |
| WO2011116867A1 (de) * | 2010-03-26 | 2011-09-29 | Merck Patent Gmbh | Benzonaphthyridinamine als autotaxin-inhibitoren |
| CA2796459C (en) | 2010-04-16 | 2016-05-24 | Salk Institute For Biological Studies | Methods for treating metabolic disorders using fgf-1 |
| EP2606031B1 (en) | 2010-08-20 | 2017-09-27 | Amira Pharmaceuticals, Inc. | Autotaxin inhibitors and uses thereof |
| US8771696B2 (en) | 2010-11-23 | 2014-07-08 | Regeneron Pharmaceuticals, Inc. | Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor |
| US8673882B2 (en) | 2011-01-20 | 2014-03-18 | University Of Tennessee Research Foundation | Inhibitors of autotaxin |
| WO2012112964A2 (en) | 2011-02-18 | 2012-08-23 | Medivation Technologies, Inc. | PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE |
| CA2829045A1 (en) | 2011-02-18 | 2012-08-23 | Medivation Technologies, Inc. | Compounds and methods for treatment of hypertension |
| WO2012123938A1 (en) | 2011-03-17 | 2012-09-20 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Quinolone analogs for treating autoimmune diseases |
| US9260416B2 (en) | 2011-05-27 | 2016-02-16 | Amira Pharmaceuticals, Inc. | Heterocyclic autotaxin inhibitors and uses thereof |
| GB2494154B (en) | 2011-08-31 | 2017-11-29 | Metaswitch Networks Ltd | Conditional telecommunications |
| WO2013054185A1 (en) | 2011-10-13 | 2013-04-18 | Pfizer, Inc. | Pyrimidine and pyridine derivatives useful in therapy |
| EP3243815B1 (en) | 2011-10-28 | 2019-07-10 | Inhibitaxin Limited | Pyridazine derivatives useful in therapy |
| JP2013129632A (ja) | 2011-12-22 | 2013-07-04 | Ono Pharmaceut Co Ltd | Ｅｎｐｐ２阻害化合物 |
| US20130270634A1 (en) | 2012-04-12 | 2013-10-17 | Richtek Technology Corporation | High voltage device and manufacturing method thereof |
| SI2861566T1 (sl) | 2012-06-13 | 2017-03-31 | F. Hoffmann-La Roche Ag | Novi diazaspirocikloalkan in azaspirocikloalkan |
| WO2014031170A1 (en) | 2012-08-22 | 2014-02-27 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| PL2900669T3 (pl) | 2012-09-25 | 2020-01-31 | F. Hoffmann-La Roche Ag | Pochodne heksahydropirolo[3,4-C]pirolu i związki pokrewne jako inhibitory autotaksyny (ATX) oraz inhibitory produkcji kwasu lizofosfatydowego (LPA) do leczenia np. chorób nerek |
| EP2935249B1 (en) | 2012-12-19 | 2018-12-12 | Novartis AG | Autotaxin inhibitors |
| US9409895B2 (en) | 2012-12-19 | 2016-08-09 | Novartis Ag | Autotaxin inhibitors |
| TWI499591B (zh) | 2013-01-11 | 2015-09-11 | Lilly Co Eli | 雙環嘧啶化合物 |
| EP3046909A4 (en) | 2013-09-17 | 2017-03-29 | Pharmakea, Inc. | Heterocyclic vinyl autotaxin inhibitor compounds |
| US9714240B2 (en) | 2013-09-17 | 2017-07-25 | Pharmakea, Inc. | Vinyl autotaxin inhibitor compounds |
| US9850203B2 (en) | 2013-09-26 | 2017-12-26 | Pharmakea, Inc. | Autotaxin inhibitor compounds |
| HRP20181290T1 (hr) | 2013-11-05 | 2018-10-19 | Bayer Cropscience Aktiengesellschaft | Novi spojevi za suzbijanje člankonožaca |
| CA2930735A1 (en) | 2013-11-22 | 2015-05-28 | Sabre Therapeutics Llc | Tetracyclic autotaxin inhibitors |
| EA201600403A1 (ru) | 2013-11-22 | 2016-10-31 | Басф Се | N-ацилиминогетероциклические соединения |
| PE20160654A1 (es) | 2013-11-22 | 2016-07-15 | Pharmakea Inc | Compuestos de inhibidor de autotaxina |
| CL2016001118A1 (es) | 2013-11-22 | 2016-12-02 | Basf Se | Compuestos heterocíclicos de n-acilimino |
| US9051320B1 (en) * | 2014-08-18 | 2015-06-09 | Pharmakea, Inc. | Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor |
| CN116059203A (zh) | 2015-05-27 | 2023-05-05 | 赛博治疗有限责任公司 | 自分泌运动因子抑制剂及其用途 |
-
2014
- 2014-11-20 PE PE2016000669A patent/PE20160654A1/es unknown
- 2014-11-20 KR KR1020227005531A patent/KR102515248B1/ko active Active
- 2014-11-20 DK DK14864293.7T patent/DK3071561T3/da active
- 2014-11-20 EA EA201690881A patent/EA030068B1/ru unknown
- 2014-11-20 CR CR20190394A patent/CR20190394A/es unknown
- 2014-11-20 EP EP21156420.8A patent/EP3878848A1/en active Pending
- 2014-11-20 LT LTEP14864293.7T patent/LT3071561T/lt unknown
- 2014-11-20 MX MX2016006623A patent/MX375706B/es active IP Right Grant
- 2014-11-20 MY MYPI2016000959A patent/MY182095A/en unknown
- 2014-11-20 PL PL14864293T patent/PL3071561T3/pl unknown
- 2014-11-20 PT PT148642937T patent/PT3071561T/pt unknown
- 2014-11-20 RS RS20210786A patent/RS62027B1/sr unknown
- 2014-11-20 HU HUE14864293A patent/HUE055213T2/hu unknown
- 2014-11-20 NZ NZ720478A patent/NZ720478A/en unknown
- 2014-11-20 BR BR112016010220-7A patent/BR112016010220B1/pt active IP Right Grant
- 2014-11-20 CN CN201480063881.XA patent/CN105793253B/zh active Active
- 2014-11-20 WO PCT/US2014/066706 patent/WO2015077503A1/en not_active Ceased
- 2014-11-20 HR HRP20210957TT patent/HRP20210957T1/hr unknown
- 2014-11-20 ES ES14864293T patent/ES2875899T3/es active Active
- 2014-11-20 JP JP2016533532A patent/JP6501367B2/ja active Active
- 2014-11-20 AU AU2014352888A patent/AU2014352888B2/en active Active
- 2014-11-20 KR KR1020167014496A patent/KR102367876B1/ko active Active
- 2014-11-20 SI SI201431843T patent/SI3071561T1/sl unknown
- 2014-11-20 CR CR20160289A patent/CR20160289A/es unknown
- 2014-11-20 SM SM20210531T patent/SMT202100531T1/it unknown
- 2014-11-20 CN CN201910686732.3A patent/CN110372671B/zh active Active
- 2014-11-20 EP EP14864293.7A patent/EP3071561B1/en active Active
- 2014-11-20 CA CA2930737A patent/CA2930737C/en active Active
-
2015
- 2015-10-29 US US14/926,877 patent/US9334261B2/en active Active
-
2016
- 2016-03-03 US US15/060,398 patent/US9468628B2/en active Active
- 2016-05-02 IL IL24538316A patent/IL245383B/en active IP Right Grant
- 2016-05-09 ZA ZA2016/03083A patent/ZA201603083B/en unknown
- 2016-05-10 PH PH12016500862A patent/PH12016500862B1/en unknown
- 2016-05-20 NI NI201600071A patent/NI201600071A/es unknown
- 2016-05-20 MX MX2020009780A patent/MX2020009780A/es unknown
- 2016-05-20 CL CL2016001231A patent/CL2016001231A1/es unknown
- 2016-09-09 US US15/261,659 patent/US9999615B2/en active Active
-
2018
- 2018-05-03 US US15/970,337 patent/US10688081B2/en active Active
-
2019
- 2019-08-09 AU AU2019213425A patent/AU2019213425B2/en active Active
- 2019-10-24 IL IL270168A patent/IL270168B/en unknown
-
2020
- 2020-05-14 US US16/874,073 patent/US11344533B2/en active Active
- 2020-08-05 ZA ZA2020/05029A patent/ZA202005029B/en unknown
-
2021
- 2021-06-23 CY CY20211100562T patent/CY1124407T1/el unknown
-
2022
- 2022-05-06 US US17/662,403 patent/US11779568B2/en active Active
-
2023
- 2023-10-04 US US18/481,141 patent/US12268668B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124729T1 (el) | Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου | |
| CY1125436T1 (el) | Αναστολεις dna-pk | |
| CY1124959T1 (el) | Αναστολεις λυσινης ειδικης απομεθυλασης-1 | |
| CY1124436T1 (el) | Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια | |
| CY1123845T1 (el) | Τοπικα φαρμακευτικα σκευασματα για την αγωγη φλεγμονωδων καταστασεων | |
| CY1125205T1 (el) | Φαρμακευτικες συνθεσεις δραστικων απο θεραπευτικη αποψη ενωσεων | |
| CY1125326T1 (el) | Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων. | |
| CY1121413T1 (el) | Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα | |
| CY1121182T1 (el) | Συνθεσεις χρησιμες για τη θεραπεια διαταραχων που σχετιζονται με kit | |
| MX375706B (es) | Compuestos de inhibidor de autotaxina. | |
| CY1120517T1 (el) | Διαρυλικες ενωσεις χρησιμες για την αγωγη ανθρωπινων νοσων στην ογκολογια, νευρολογια και ανοσολογια | |
| CY1123295T1 (el) | Κρυσταλλικες μορφες της 5-χλωρο-ν4-[-2-(διμεθυλοφωσφορυλο) φαινυλο]-ν2-{2-μεθοξυ-4-[4-(4-μεθυλοπιπεραζιν-1-υλο)πιπεριδιν- 1-υλο]πυριμιδινο-2,4-διαμινης | |
| CY1124704T1 (el) | Παραγωγα sobetirome | |
| MX373045B (es) | Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo. | |
| MX386935B (es) | Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades. | |
| CY1116424T1 (el) | Παραγωγο αδενινης ως αναστολεας ρι3κ | |
| MX378273B (es) | Compuestos activos hacia bromodominios. | |
| CY1121806T1 (el) | Ιμιδαζοπυραζινονες ως αναστολεις pde1 | |
| CY1120751T1 (el) | Αναστολεις ετεροδικυκλοαρυλιου του rorc2 και μεθοδοι χρησης αυτων | |
| CY1123216T1 (el) | Αναστολεις της gls1 για την αντιμετωπιση νοσων | |
| EA201792604A1 (ru) | Ингибиторы аутотаксина и их применения | |
| PL410665A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
| CL2018000565A1 (es) | Compuestos derivados de piridinona dicarboxamida, inhibidores de bromodominio; composicion farmaceutica; combinacion farmaceutica; utiles en el tratamiento de enfermedades autoinmunitarias, inflamatorias, virales y cancer, entre otras. | |
| EA201791454A1 (ru) | Лекарственные формы для трансдермального введения |